1/24
BPMH
what is psychosis
a mental state that is characterised by a combination of symptoms, including unusual experiences, belief, and thoughts, which arise from physical or psychological causes
symptoms are seen in people with SCZ or SSDs
SCZ spectrum disorders
according to NICE clinical knowledge summaries
approximately 0.5% of people aged 16+ have a SSD diagnosis
more common in males than females, ratio of 1.4:1
typical age of onset is 20-25 for males, and 25-30 for females
characterisation of psychosis symptoms
positive → experiencing something new, e.g. hallucinations, delusions, and illusions
negative → loss of function, e.g. decreases emotional expression and motivation
cognitive → disorganised thinking
motor → changes in movement, e.g. tics, catatonia (freezing)
DSM-5 diagnosis
the presence of symptoms is not ‘all or none’, people vary in severity of symptoms
DSM-5 has made available the Clinical Rated Dimensions of Psychosis Symptoms Severity scale
there are six major SSDs, diagnosed as primary psychotic disorders if disturbances cannot be explained by other condition, background, or a drug/substance
progression of SSDs
genetics and adverse early life experiences may make an individual susceptible to psychosis
some features of SSDs may be present at a young age, and it is only later that delusions and hallucinations emerge
early symptoms that are present before official diagnosis are prodromal symptoms
enlargement of brain ventricles
SCZ patients who have a poor treatment outcome (>50% hospitalisation) had larger lateral ventricles than those with successful treatments
may be due to shrinkage in surrounding brain tissue
antipsychotic medications may be associated with a decrease in lateral ventricle size
hippocampus
may be an inverse relationship between hippocampal size and lateral ventricle size
studies have observed significant decreases in hippocampal volume in SSDs, more so for patients with poor treatment outcome
however hippocampal neurons are more active in patients than controls
this may not be due to number of neurons but type, more excitatory pyramidal glutamatergic neurons than interneurons
hippocampal neuron differences
some patients with SCZ display a marked reduction in the density of GABAergic interneurons on the hippocampus
when a excitatory neuron is no longer inhibited by another cell it becomes more active (is disinhibited)
impacts of dysregulated hippocampal function
vital for formation of new memories, this is disrupted in SSDs
SCZ patients have difficulty remembering words presented to them
disrupted spatial memory
reduced ability to habituate ever-present stimuli
stress
when one experiences stressful events, the HPA axis becomes activated, causing an increase in cortisol
high levels of which can be damaging to the hippocampus
individuals that have had an initial psychotic episode show both increases cortisol levels and decreased hippocampal volume
for some people, particularly those with a family history of SSDs, stress could be a trigger for the development of psychotic symptoms
dopamine
within the midbrain, distinct small groups of DA cells project to forebrain targets
excitatory glutamatergic pyramidal neurons of the hippocampus are thought to be overactive in SSD patients
evidence suggests that such excessive excitation of these neurons indirectly results in exaggerated dopamine NT in the brain
dopamine pathway
most cell bodies in the NAc, which receive glutamate and DA input, are GABAergic and are called medium spiny neurons (MSNs)
MSNs project to another nucleus, the ventral pallidum (VP)
many cell bodies in the VP are GABAergic, and these neurons project to the ventral tegmental area (VTA)
dopamine signalling in SSDs
an increase in glutamate release in NAc which excited MSNs
MSNs release more GABA in VP, inhibiting VP neurons
VP is now less likely to inhibit VTA
VTA dopamine neurons disinhibited- more likely to be active and release dopamine in NAc
DA in the striatum is elevated in SCZ
chlorpromazine
in addition to increased NAc DA, people with SSDs may have increased striatal D2 receptors
this drug can alleviate positive symptoms of psychosis, able to antagonise DA D2-type receptors
these D2 antagonists are called ‘typical’ or 1st gen antipsychotics
clozapine
targets D2-type receptors, but also affects other receptors and NT systems, and may impact different brain regions in unique ways
more effective at reducing aspects of psychosis
the original ‘atypical’ or 2nd gen antipsychotic. these are believed to alleviate hypofrontality in SSDs, and may decrease positive, negative, and cognitive symptoms of SSDs
side effects of antipsychotics
extra pyramidal side effects (Parkinson, akathisia, dystonia, tardive diskinesia)
prolactin elevation (amenorrhea, galactorrhoea)
dysphoria, anhedonia, depressed mood
DSM-5: stimulant use disorder (SUD)
pattern of amphetamine-type substance, cocaine, or other stimulant use leading to clinically significant impairment or distress. must show 2+ symptoms within 12 months.
prevalence of drug use
changes dramatically as a function of a number of factors, including drug type, sex/gender, age, country/region, legal system
drug prevalence data approximated via residue concentration in wastewater
street drugs almost always contain pollutants
drug users may unknowingly take more than one drug
basic bio of addiction
most potentially addictive drugs increase DA transmission
there are however many biophysical influences
normal DA release in brain
GABA interneurons are located in the VTA and can release GABA onto DA neurons
DA neurons hyperpolarise and activation is blunted
DA neurons cannot fire APs
DA release onto NAc is minimised
effect of opioids on DA release in brain
opioid-producing neurons are also in VTA
they release β-endorphine (an endogenous opioid), which binds to μ-opioid receptors on GABA terminals
terminal is hyperpolarised
GABA release is prevented
DA neuron is disinhibited, allowing it to fire APs
DA is released in the NAc
sensitisation
repeated exposure enhances ability of the drug to increase DA release in the ventral striatum, including NAc
incentive salience model of motivation
with repeated drug or gambling exposure, wanting may become enhanced (sensitised), and process facilitated by exaggerated DA transmission
excessive wanting can lead to addictive behaviours, even when pleasure associated with the activity decreases
this is magnified by experience with uncertainty, and reward-predictive cues, which are salient and can drive relapse
cues
DA provides a link, encoding both learning and uncertainty
exposure to cues that predict reward evokes DA transmission
when there is a high level of uncertainty, DA neurons increase their activity between the cue presentation and potential event / reward
DA levels may fluctuate according to lifetime drug use
cues associated with drug use can activate brain pathways responsible for relapse
in drug addiction, cues can become inappropriately salient due to altered DA signalling in the brain
these salient cues can be distracting and negatively impact behaviour
salience of cues and DA are also relevant to psychosis
environment / genetic factors
dysregulated firing and / or DA release
aberrant sense of novelty and an abnormal assignment of salience to stimuli, and internal representation
compounded by a lack of habituation
delusions are a cognitive schema that the patient develops to explain aberrant salience experience
when this aberrant salience captures behaviour or causes distress, leads to attention
antipsychotics block dopamine and dampen the salience of normal events